- Founded in: 2014
- Number of employees: 20
- Country: France
- Investors: Medevice Capital Business Angels
- Market: Fine Chemistry, Advanced chemicals, Pharmaceutical intermediates and active substances, Nutraceutical, Cosmetic industry and Bio-control.
- Website: www.abolis.fr
Which input provides your business model/core technology towards a bio-based economy?
Abolis develops a portfolio of technologies to design, construct and scale-up tailor-made bioprocesses for any arbitrary molecule in order to produce them using fermentation of renewable sugars. Abolis works in partnership with its customers from the chemical industry and a network of collaborators to cover the entire development chain from the need of a given molecule to the delivery of the final process book.
Which market/clients do you address and which short-term/long-term goals do you have?
Abolis already works in partnership with a pharmaceutical and a middle market cosmetic ingredient producer. We aim at developing more deals in these two markets, as well as expanding applications in fine chemistry, nutraceuticals and bio-control applications.
What makes your approach unique compared to other stakeholders in the field?
Abolis is very experience with design, implementation and optimization of long metabolic pathways. We have a long experience in very complex polyphenol production using metabolic engineering. Abolis works with its partners using an agile, industrial Go/NoGo driven development plan.
You can meet Abolis in Toulouse at the START-UP VILLAGE @EFIB on 17-18 October.